Group 1: Oil and Gas Sector - Oil stocks experienced a decline, with Sinopec (00386) down 3.89%, PetroChina (00857) down 3.17%, and CNOOC (00883) down 2.79%. This follows a drop in WTI crude oil futures by 2.77% to $62.84 per barrel and Brent crude by 2.71% to $67.52 per barrel [1] Group 2: Renewable Energy Sector - Solar stocks fell collectively, with Xinyi Solar (00968) down 3.62% and New Special Energy (01799) down 3.61%. The rise in silver prices has increased silver paste costs, impacting the battery and component sectors [1] Group 3: Precious Metals Sector - Lao Poo Gold (06181) saw a nearly 5% drop. Bank of America Securities reported that the company is expected to benefit from rising gold prices, with a projected revenue increase of 165% year-on-year for the second half of last year [1] Group 4: Pharmaceuticals - Zai Lab (09688) rose by 7% after its injection drug ZL-1310 was proposed for breakthrough therapy designation for extensive-stage small cell lung cancer (ES-SCLC), showing promising early clinical data [2] Group 5: Precision Manufacturing - China High Precision (00591) fell over 18% after issuing a profit warning, expecting a profit of approximately RMB 2.5 million to RMB 4.5 million for the six months ending December 31, 2025, due to project delays in the oil and petrochemical sectors [2] Group 6: Non-Ferrous Metals - Non-ferrous stocks faced significant declines, with China Nonferrous Mining (01258) down 5.08% and Zijin Mining (02899) down 5.29%. This is attributed to a "de-risking" sentiment in global financial markets, leading to a sell-off in precious metals [3] Group 7: Biotechnology - Xiansheng Pharmaceutical (02096) increased over 4.4% after announcing a licensing agreement with AbbVie for the investigational drug SIM0500, which includes upfront payments and potential milestone payments totaling up to $1.055 billion [3] Group 8: Gaming Sector - Gaming stocks declined, with Melco International Development (00200) down 6.21%. Wynn Macau reported a 7% year-on-year drop in EBITDA for Q4 2025, which was below market expectations [4] Group 9: Oilfield Services - Anton Oilfield Services (03337) rose over 9% after announcing a profit forecast of approximately RMB 360 million to RMB 380 million for 2025, representing a significant year-on-year increase of 48.4% to 56.6% [4] Group 10: U.S. Market Movements - Arko Petroleum (APC.US) opened with a 2.5% decline after its market debut. The company delivered 1.5 billion gallons of fuel in the nine months ending September 30, 2025 [5] - Albemarle (ALB.US) fell 9.41% despite a 16% year-on-year increase in Q4 sales to $1.4 billion, reporting a net loss of $414 million [5] - Boeing (BA.US) rose 1.31% as it plans to increase the monthly production of its 737 series aircraft to 63 units in the coming years [5] Group 11: Technology Sector - Cisco (CSCO.US) dropped 12.32% as it projected a decline in adjusted gross margin for Q3, indicating a worsening trend compared to previous quarters [7] - Storage stocks saw gains, with SanDisk (SNDK.US) up 5.16% and Western Digital (WDC.US) up 3.78% [7]

Core Viewpoint - Zai Ding Pharmaceutical (09688) has seen a stock price increase of over 5%, currently trading at HKD 15.26, with a transaction volume of HKD 81.97 million, following the announcement of its injection drug ZL-1310 being considered for breakthrough therapy designation for extensive-stage small cell lung cancer (ES-SCLC) patients [1] Group 1: Drug Development and Clinical Trials - ZL-1310 has shown outstanding efficacy data in early clinical studies, particularly in patients receiving second-line treatment and those with brain metastases, indicating its potential as a breakthrough therapy in the SCLC treatment field [1] - The company plans to initiate three registration clinical trials for its targeted DLL3 ADC drug Zocilurtatug by the end of 2026, covering small cell lung cancer and neuroendocrine cancer [1] Group 2: Revenue Generation and Strategic Development - The company is generating stable revenue by introducing and commercializing overseas products while leveraging its cross-border platform to promote global development of its innovative pipeline [1] - Zai Ding Pharmaceutical possesses several early-stage global assets with differentiated potential, such as ZL-1503 and ZL-6201, which support its long-term value creation [1]

Group 1 - The core stock of Zai Lab (09688) has increased by over 5%, currently trading at HKD 15.26 with a transaction volume of HKD 81.97 million [1] - Zai Lab's injectable ZL-1310 is proposed to be included as a breakthrough therapy for extensive-stage small cell lung cancer (ES-SCLC) patients who experience disease progression during or after first-line platinum-based therapy [1] - Early clinical research data for ZL-1310 shows significant efficacy, particularly in patients receiving second-line treatment and those with brain metastases, indicating its potential as a breakthrough therapy in the SCLC treatment field [1] Group 2 - Haitong International's report highlights that the company is generating stable income through the introduction and commercialization of overseas products while promoting global development of its innovative pipeline via cross-border platforms [1] - The core pipeline includes the DLL3-targeted ADC drug Zocilurtatug, which is planned to initiate three registration clinical trials by the end of 2026, covering small cell lung cancer and neuroendocrine cancer [1] - The company also possesses several early-stage global assets with differentiated potential, such as ZL-1503 and ZL-6201, which collectively support its long-term value creation [1]

中国银河证券研报认为，科技板块仍是中长期投资主线，经历近期的回调后，估值压力下降，相关板块 有望反弹回升，预计春节前后港股市场震荡上行。 港股通科技ETF海富通(513860)，紧密跟踪中证港股通科技指数，从港股通范围内选取50只市值较大、 研发投入较高且营收增速较好的科技龙头上市公司证券作为指数样本，截至最新，指数前五大中证一级 行业为：可选消费（37.02%）、信息技术（27.98%）、医药卫生（17.17%）、通信服务（16.31%）、 工业（1.52%）。场外联接(A类：021464；C类：021465) 风险提示：以上信息仅供参考，不构成投资建议。基金有风险，投资需谨慎。 截至2026年2月13日9:50，港股通科技ETF海富通(513860)小幅回调，成分股方面，九方智投控股涨超 5%，再鼎医药、联想集团、国药控股等涨超1%，信达生物、中芯国际、华虹半导体等跟涨。 资金净流入方面，Choice数据统计，截至2026年2月12日，港股通科技ETF海富通(513860)近3个月净流 入额增长 3.21亿元，近6个月净流入额增长18.26亿元，长期看增长显著。 从估值层面来看，港股通科技ETF海富通跟踪 ...

Core Viewpoint - Morgan Stanley forecasts that WuXi Biologics (02269) stock price will rise in the next 45 days, with a probability between 70% to 80% [1] Financial Projections - The earnings forecast for WuXi Biologics for 2026 to 2030 has been raised by 4% to 10% due to accelerated revenue growth and margin expansion [1] - Target price has been increased from HKD 45 to HKD 50, maintaining an "Overweight" rating [1] Company Performance Indicators - The company previously issued a positive earnings forecast, with management indicating accelerated growth for the fiscal year 2026 [1] - The number of integration projects for 2025 is expected to increase by 16%, alongside strong momentum in research services, indicating robust performance for 2026 [1] - The momentum in research services is anticipated to generate revenue related to intellectual property (IP), further enhancing profitability [1] Strategic Partnerships and Growth - Recently, the company has entered into licensing agreements with Vertex and Zai Lab (09688) [1] - Strong growth is expected in the manufacturing sector, with the company mentioning "multiple blockbuster drugs" on the horizon [1] - The company completed 28 Process Performance Qualifications (PPQ) in 2025, a 75% year-on-year increase, viewed as a leading indicator for future commercialization contracts [1]

Core Viewpoint - Zai Lab Limited (09688.HK) will present its financial performance for the year ending December 31, 2025, to the board for approval on February 26, 2026, in accordance with US GAAP and SEC regulations [1] Group 1 - The board meeting is scheduled for February 26, 2026, to review and approve the annual financial results [1] - If approved, the annual performance announcement will be published on the Hong Kong Stock Exchange and the company's website on the same day [1]

再鼎醫藥有限公司（「本公司」）謹此公佈，本公司董事會（「董事會」）將於 2026 年 2 月 26 日 （星期四）審議及批准（其中包括）根據美國公認會計準則（「美國公認會計準則」）及美國證 券交易委員會（「美國證交會」）的適用規則編製的本公司及其附屬公司截至 2025 年 12 月 31 日 止年度的財務業績（「年度業績」）及其發佈。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不會對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔 任何責任。 倘年度業績獲董事會批准，本公司將於 2026 年 2 月 26 日（星期四）在香港聯合交易所有限公司網 站 www.hkexnews.hk 及本公司網站 http://ir.zailaboratory.com 發佈關於年度業績的公告。 在年度業績獲批准及發佈後，本公司管理層計劃在 2026 年 2 月 26 日（星期四，美國東部時間）上 午 8:00/2026 年 2 月 26 日（星期四，香港時間）下午 9:00 舉行電話會議及網絡直播，以討論年度業 績並回答提問（如 ...

Domestic Market Overview - The domestic market experienced a slight increase with reduced trading volume on February 10, closing with the Shanghai Composite Index at 4128.37 points, up 0.13%, and the Shenzhen Component Index at 14210.63 points, up 0.02% [1][10] - The total trading volume for the A-share market was 21,247 billion, showing a decrease compared to the previous day [1][10] - Among the 30 sectors tracked, 12 sectors saw gains, with media, home appliances, and coal leading the increases, while real estate, food and beverage, and retail sectors faced significant declines [1][10] Overseas Market Overview - The U.S. stock market showed mixed results on February 10, with the Dow Jones Industrial Average rising by 0.1%, while the S&P 500 and Nasdaq fell by 0.33% and 0.59%, respectively [2][10] - Notable stock movements included Disney and Home Depot rising over 2%, while Intel dropped more than 6% [2][10] - The Nasdaq Golden Dragon China Index increased by 0.87%, with notable gains from Hesai Technology and Zai Lab, both rising over 6% [2][10] News Highlights - The article from Qiushi Network emphasizes the importance of forward-looking layouts and the development of future industries to seize technological and industrial advantages, which is essential for promoting high-quality development [3][13] - The State Administration for Market Regulation has approved a batch of important national standards covering emerging fields, transportation logistics, ecological protection, and safety production, which will enhance the quality of life and safety [3][14][15] - The Shanghai Metropolitan Area's land space planning draft has been made public, aiming to establish a world-class modern metropolitan area by 2035 [3][18] Driving Factors - The People's Bank of China indicated a commitment to maintaining a moderately loose monetary policy, utilizing various tools to ensure liquidity and favorable financing conditions [11] - On the same day, 2,195 stocks rose while 3,128 fell, indicating a mixed market sentiment with 209 stocks gaining over 5% and 76 losing over 5% [11]

Market Overview - The Hong Kong stock market experienced fluctuations, with the Hang Seng Index closing at 23,831 points, down 145 points or 0.61% [1] - The market turnover decreased to 82.799 billion HKD, with net inflows of 484 million HKD recorded in the Hong Kong Stock Connect [1] - The US stock market showed mixed results, with the Dow Jones rising 0.1% to a new closing high, while the S&P 500 and Nasdaq fell by 0.33% and 0.59% respectively [2] Sector Performance - In the Hong Kong market, local real estate, software, and 5G sectors saw significant declines, while gold stocks performed well [1] - Biotechnology and cultural media sectors were active, with the Hang Seng Index rising 0.58% and the Hang Seng Technology Index increasing by 0.62% [1] - Notable stock performances included a 5.5% increase for CSPC Pharmaceutical Group and a 15.4% rise for China Literature [1] Investment Opportunities - The report emphasizes the importance of "technological self-reliance" and AI applications as key themes for future growth in the Hong Kong market, suggesting that leading companies in these sectors may benefit from long-term development opportunities [3] - The report recommends focusing on sectors supported by policies aimed at expanding domestic consumption, such as sports apparel and non-essential services [3] - It highlights the value of investing in state-owned enterprises with relatively low valuations and high dividends across various industries [3] Company Highlights - ByteDance's subsidiary Doubao launched a New Year campaign, distributing red envelopes and promoting AI applications, which may boost demand for upstream GPU and AI chips [9] - Innovent Biologics announced a strategic partnership with Eli Lilly, with a total transaction value of up to 8.85 billion USD, indicating strong market confidence in China's innovative drug pipeline [9] - The report suggests monitoring leading companies in the domestic semiconductor foundry industry, such as Hua Hong Semiconductor and SMIC, as they are expected to benefit from favorable policies [9]

Market Overview - The Hong Kong stock market opened slightly higher on February 11, with the Hang Seng Index at 27,246.18 points, up 63.03 points, a gain of 0.23% [1] - The Hang Seng Tech Index opened at 5,462.70 points, increasing by 11.67 points, a rise of 0.21% [2] Company Focus - The stock of Zhipu AI (HK02513), referred to as the first large model stock, opened over 4% higher and has accumulated a gain of over 60% this week [3] - Zhipu's core competitive advantages include a fully self-developed technology system, leading model performance, an open-source ecosystem, and deep adaptation to domestic computing power. The company has a high proportion of R&D personnel at 74%, with a core team from Tsinghua KEG Laboratory, showcasing strong academic accumulation in natural language processing [5] - The GLM series has rapidly iterated, with GLM-4.7 performing exceptionally well in programming scenarios. The AutoGLM enables AI to autonomously operate smartphones and computer GUIs, marking a new paradigm in agent technology. Multi-modal capabilities cover text-to-image, text-to-video, and visual understanding, with CogView-4 and CogVideoX ranking highly in open-source evaluations. These technological advantages have been translated into practical applications across various sectors, including technology, finance, government, healthcare, and manufacturing [5] Other Company Updates - Shanghai Xiaonanguo (HK03666) saw a decline of over 16% in early trading. The company announced a strategic restructuring, confirming the temporary suspension of operations for 10 of its Shanghai restaurants. It clarified that claims regarding non-refundable deposits and prepaid cards were incorrect, as it is processing refunds for customers [7] - The market showed mixed performance among tech stocks, with Baidu, Kuaishou, and Bilibili rising over 1%, while Tencent fell over 1%. Innovative drug concept stocks were active, with Zai Lab rising over 3%, and automotive stocks also saw some increases, with BYD up over 1% [7] Market Outlook - CICC's latest view indicates that the recent pullback in the Hong Kong stock market is a result of weak fundamentals, concerns over tightening liquidity, and a decline in the attractiveness of Hong Kong's unique market structure. The overall credit cycle is experiencing turbulence, limiting the market index's potential, with the Hang Seng Index expected to range between 28,000 and 29,000 points [8] - In the short term, the market may have overreacted to various factors, including the nomination of Waller as the next Fed chair and concerns over AI bubbles and the collapse of old technology applications. There may be potential for upward correction after a pullback. In the medium term, a 3% to 4% growth in earnings for Hong Kong stocks is anticipated, which could drive the Hang Seng Index higher [8] - CICC suggests that the main investment focus should follow the direction of credit expansion, particularly in AI technology, cyclical sectors, consumption, and dividends, with AI technology and cyclical sectors being the primary focus of current credit expansion [8]